Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Inge Marie Svane

Københavns Universitet

Denmark

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Pharmacotherapy

60%

Immunology

100%

Immunotherapy

60%

Oncology

50%

Cancer Therapy

40%

Targeted Therapy

40%

Immunomodulation

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles30

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Article Link

Year:

2025

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial

Article Link

Year:

2025

Identification of protein biomarker candidates associated with organ-specific immune-related toxicity and response to management by plasma proteomics.

Article Link

Year:

2025

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Article Link

Year:

2025

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

Article Link

Year:

2025

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Article Link

Year:

2025

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Article Link

Year:

2025

Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.

Article Link

Year:

2025

Unlocking tumor-infiltrating lymphocyte potential with CRISPR-Cas9.

Article Link

Year:

2025

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Article Link

Year:

2025

Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib

Article Link

Year:

2024

Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort

Article Link

Year:

2024

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression

Article Link

Year:

2024

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

Article Link

Year:

2024

Harnessing neoantigen-specific T cells for precision cancer immunotherapy.

Article Link

Year:

2024

Biomarkers for response to TIL therapy: a comprehensive review.

Article Link

Year:

2024

Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.

Article Link

Year:

2024

Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE project.

Article Link

Year:

2024

New expert advice on cancer in pregnancy.

Article Link

Year:

2024

Reduced mitochondrial respiration in peripheral T cells after paediatric heamatopoietic stem cell transplantation.

Article Link

Year:

2024

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

Article Link

Year:

2023

of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Article Link

Year:

2023

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Article Link

Year:

2023

Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.

Article Link

Year:

2023

ASO Visual Abstract: Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma-A National Cohort Study of 1480 Patients.

Article Link

Year:

2023

Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours-Authors' reply.

Article Link

Year:

2023

TIL Therapy: Facts and Hopes.

Article Link

Year:

2023

Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.

Article Link

Year:

2023

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.

Article Link

Year:

2023

Combination therapy with immune check point inhibitors and acute kidney injury.

Article Link

Year:

2023

Collaborators18

Carolina Barra

Technical University of Denmark

DENMARK

Maartje Schermer

Erasmus University Rotterdam

NETHERLANDS

Melanie Lindenberg

University of Twente

NETHERLANDS

Nikolaj Pagh Kristensen

University Hospital Erlangen

GERMANY

Eva Ellebaek

Copenhagen University Hospital

DENMARK

Jorge Sierra-Pérez

Associate Professor

Universidad de Zaragoza

SPAIN

Akseli Hemminki

University of Helsinki

FINLAND

Özcan Met

Københavns Universitet

DENMARK

Elena Semino

University of Lancaster

UNITED KINGDOM

Valesca Retèl

Erasmus University Rotterdam

NETHERLANDS

Christina H Ruhlmann

Associate Professor

University of Southern Denmark

DENMARK

Paul Rayson

University of Lancaster

UNITED KINGDOM

Mads Hald Andersen

Professor, dr.techn., Director

DENMARK

Fernando Secomandi

Delft University of Technology

NETHERLANDS

Henrik Schmidt

Consultant, Ass. Prof

Aarhus University Hospital

DENMARK

Marco Donia

Copenhagen University Hospital

DENMARK

Renske ten Ham

Assistant Professor

UMC Utrecht

NETHERLANDS

Mona Aarenstrup Karlsen

Copenhagen University Hospital

DENMARK

How do I reach out?

Meet Kite AI

Inge Marie Svane

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles30

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial

Identification of protein biomarker candidates associated with organ-specific immune-related toxicity and response to management by plasma proteomics.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.

Unlocking tumor-infiltrating lymphocyte potential with CRISPR-Cas9.

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib

Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

Harnessing neoantigen-specific T cells for precision cancer immunotherapy.

Biomarkers for response to TIL therapy: a comprehensive review.

Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.

Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE project.

New expert advice on cancer in pregnancy.

Reduced mitochondrial respiration in peripheral T cells after paediatric heamatopoietic stem cell transplantation.

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.

ASO Visual Abstract: Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma-A National Cohort Study of 1480 Patients.

Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours-Authors' reply.

TIL Therapy: Facts and Hopes.

Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.

Combination therapy with immune check point inhibitors and acute kidney injury.

Collaborators18

Carolina Barra

Maartje Schermer

Melanie Lindenberg

Nikolaj Pagh Kristensen

Eva Ellebaek

Jorge Sierra-Pérez

Akseli Hemminki

Özcan Met

Elena Semino

Valesca Retèl

Christina H Ruhlmann

Paul Rayson

Mads Hald Andersen

Fernando Secomandi

Henrik Schmidt

Marco Donia

Renske ten Ham

Mona Aarenstrup Karlsen

How do I reach out?

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.